1. Home
  2. CME vs TOVX Comparison

CME vs TOVX Comparison

Compare CME & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CME
  • TOVX
  • Stock Information
  • Founded
  • CME 1898
  • TOVX 2001
  • Country
  • CME United States
  • TOVX United States
  • Employees
  • CME N/A
  • TOVX N/A
  • Industry
  • CME Investment Bankers/Brokers/Service
  • TOVX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CME Finance
  • TOVX Health Care
  • Exchange
  • CME Nasdaq
  • TOVX Nasdaq
  • Market Cap
  • CME N/A
  • TOVX 3.5M
  • IPO Year
  • CME 2002
  • TOVX 2006
  • Fundamental
  • Price
  • CME $238.53
  • TOVX $1.14
  • Analyst Decision
  • CME Hold
  • TOVX Strong Buy
  • Analyst Count
  • CME 16
  • TOVX 1
  • Target Price
  • CME $229.69
  • TOVX $6.00
  • AVG Volume (30 Days)
  • CME 2.6M
  • TOVX 96.3K
  • Earning Date
  • CME 02-12-2025
  • TOVX 11-12-2024
  • Dividend Yield
  • CME 4.36%
  • TOVX N/A
  • EPS Growth
  • CME 13.48
  • TOVX N/A
  • EPS
  • CME 9.51
  • TOVX N/A
  • Revenue
  • CME $6,034,400,000.00
  • TOVX N/A
  • Revenue This Year
  • CME $11.04
  • TOVX N/A
  • Revenue Next Year
  • CME $2.60
  • TOVX N/A
  • P/E Ratio
  • CME $25.08
  • TOVX N/A
  • Revenue Growth
  • CME 13.05
  • TOVX N/A
  • 52 Week Low
  • CME $190.70
  • TOVX $1.14
  • 52 Week High
  • CME $249.02
  • TOVX $17.00
  • Technical
  • Relative Strength Index (RSI)
  • CME 57.47
  • TOVX 36.15
  • Support Level
  • CME $234.06
  • TOVX $1.23
  • Resistance Level
  • CME $238.60
  • TOVX $1.21
  • Average True Range (ATR)
  • CME 4.54
  • TOVX 0.07
  • MACD
  • CME -0.51
  • TOVX 0.01
  • Stochastic Oscillator
  • CME 29.88
  • TOVX 0.00

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Share on Social Networks: